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IMPORTANCE D-dimermeasurement is an important step in thediagnostic strategyof clinically
suspectedacutepulmonary embolism (PE), but its clinical usefulness is limited in elderly patients.
OBJECTIVE To prospectively validate whether an age-adjusted D-dimer cutoff, defined as
age × 10 in patients 50 years or older, is associated with an increased diagnostic yield of
D-dimer in elderly patients with suspected PE.
DESIGN, SETTINGS, AND PATIENTS Amulticenter, multinational, prospectivemanagement
outcome study in 19 centers in Belgium, France, the Netherlands, and Switzerland between
January 1, 2010, and February 28, 2013.
INTERVENTIONS All consecutive outpatients who presented to the emergency department
with clinically suspected PE were assessed by a sequential diagnostic strategy based on the
clinical probability assessed using either the simplified, revised Geneva score or the 2-level
Wells score for PE; highly sensitive D-dimer measurement; and computed tomography
pulmonary angiography (CTPA). Patients with a D-dimer value between the conventional
cutoff of 500 μg/L and their age-adjusted cutoff did not undergo CTPA and were left
untreated and formally followed-up for a 3-month period.
MAIN OUTCOMES ANDMEASURES The primary outcomewas the failure rate of the diagnostic
strategy, defined as adjudicated thromboembolic events during the 3-month follow-up
period among patients not treated with anticoagulants on the basis of a negative
age-adjusted D-dimer cutoff result.
RESULTS Of the3346patientswith suspectedPE included, theprevalenceof PEwas 19%.
Among the2898patientswith anonhighor anunlikely clinical probability, 817patients (28.2%)
hadaD-dimer level lower than500μg/L (95%CI, 26.6%-29.9%)and337patients (11.6%)hada
D-dimerbetween500μg/L and their age-adjusted cutoff (95%CI, 10.5%-12.9%). The3-month
failure rate inpatientswith aD-dimer level higher than500μg/Lbutbelow theage-adjusted cut-
offwas 1 of 331 patients (0.3%[95%CI,0.1%-1.7%]). Among the766patients 75 years or older, of
whom673hadanonhigh clinical probability, using the age-adjusted cutoff insteadof the500
μg/L cutoff increased theproportionof patients inwhomPEcouldbeexcludedon thebasis of
D-dimer from43of673patients (6.4%[95%CI, 4.8%-8.5%) to200of673patients (29.7%
[95%CI, 26.4%-33.3%),without any additional false-negative findings.
CONCLUSIONS AND RELEVANCE Comparedwith a fixed D-dimer cutoff of 500 μg/L, the
combination of pretest clinical probability assessment with age-adjusted D-dimer cutoff was
associated with a larger number of patients in whom PE could be considered ruled out with a
low likelihood of subsequent clinical venous thromboembolism.
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T he standard diagnostic approach of patientswith clini-cally suspected acute pulmonary embolism (PE) relieson sequential diagnostic tests, suchas clinical probabil-
ity assessment, plasma D-dimer measurement, compression
ultrasonography, computed tomography pulmonary angiog-
raphy (CTPA), or ventilation-perfusion lung scan.1,2
TheD-dimer testhasbeenextensively evaluated in theex-
clusion of PE, particularly among outpatients.3 The enzyme-
linked immunosorbentassay (ELISA)D-dimer test andsecond-
generation latex agglutination tests (immunoturbidimetric
tests)havea remarkablyhighsensitivity andhavebeenproven
safe first-line tests in association with clinical probability to
rule out PE in outcome studies.4,5
Several studies have shown that D-dimer levels increase
with age.6,7 As a result, the clinical usefulness of the test, the
proportion of the patients with a D-dimer level lower than
the predetermined cutoff value (500 μg/L for most available
commercial assays) and in whom the diagnosis of PE may be
ruledoutby the test, is reduced. In aprevious study, theELISA
D-dimer testwasable to ruleoutPE in60%ofpatientsyounger
than 40 years, but in only 5%of patients older than 80 years,8
thus limiting the yield and cost-effectiveness of noninvasive
diagnosis in this subgroup of older, often fragile, patients.
Weretrospectivelyderivedandvalidatedthevalueofapro-
gressiveD-dimercutoff adjusted toage inawidesampleof 1712
patients. The optimal age-adjusted cutoff was defined as pa-
tient’s age multiplied by 10 in patients 50 years or older.9 In
the retrospective validation analysis, the age-adjusted
D-dimer cutoff would have increased by about 20% the
number of patients inwhom theD-dimer testwas considered
negativewithout increasing the false-negative ratewhencom-
pared with the usual 500 μg/L cutoff. The results were par-
ticularly appealing in patients older than 80 years—the
age-adjusted cutoff allowed an increase in the proportion of
patients with a negative D-dimer result from 9% to 21%with-
out any false-negative test.9
However, prospective validation of this age-adjusted cut-
off was indicated before this strategy could be implemented
in clinical practice.Hence,weassessed its failure rate anduse-
fulness inaprospectivemanagementoutcomestudy, inwhich
consecutive outpatients with suspected PE were left un-
treatedon thebasis of anegative age-adjustedD-dimer test re-
sult, in combination with a clinical probability assessment.
Methods
Study Setting
The study was designed as a multicenter, multinational, pro-
spective diagnostic management outcome study, involving 19
hospitals in 4 European countries (Belgium, France, the Neth-
erlands, andSwitzerland). Theethics committeesof all partici-
pating institutionsapprovedthestudy. InBelgium,France, and
Switzerland, patients provided written informed consent be-
fore enrollment. In the Netherlands, the ethics committee
judged that informed consent was not necessary, but patients
were in all cases informed by the treating physician about the
protocol and about the 3-month phone call follow-up.
Patients
Consecutive outpatientswhopresented to the emergencyde-
partmentof theparticipatinghospitalswereeligible if theyhad
a clinical suspicion of PE defined as an acute onset or wors-
ening shortness of breath or chest pain without another ob-
vious etiology. Patients were excluded if a PE suspicion was
raised more than 24 hours after admission to the hospital, if
they were receiving anticoagulant therapy for another indi-
cation (eg, atrial fibrillation), or if they had an allergy to con-
trast medium, impaired renal function (creatinine clearance
less than 30mL/min as per the Cockcroft-Gault formula), life
expectancy of less than 3 months, ongoing pregnancy, or in-
accessibility for follow-up.
Diagnostic Strategy
Clinical probability was assessed using either the simplified,
revised Geneva score10,11 or the 2-level Wells score for PE2,12
(Table 1). Patientswith ahighor a likely clinical probability di-
rectly proceeded to CTPA. In patients with a low/intermedi-
ate or unlikely clinical probability, a D-dimer test was per-
formed. The D-dimer result was interpreted according to the
age-adjusted cutoff: inpatients younger than50years, PEwas
excluded in those with a D-dimer value lower than 500 μg/L.
In patients 50 years or older, the D-dimer test result was con-
siderednegative in thosewithaD-dimervalue lower than their
Table 1. The Simplified, RevisedGeneva Score and the 2-LevelWells Score
Score Points
Simplified, revised Geneva score11
Age >65 y 1.0
Previous history of PE or DVT 1.0
Surgery or fracture within 1 mo 1.0
Active malignancy 1.0













Clinical signs and symptoms of DVT 3.0
Immobilization or surgery in the previous 4 wk 1.5
Heart rate greater than 100 beats/min 1.5
Previous history of PE or DVT 1.5
Hemoptysis 1.0
Malignancy 1.0




Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolism.
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age multiplied by 10. Six different quantitative high-
sensitivity D-dimer assayswere used: the VIDASD-Dimer Ex-
clusion test (bioMérieux), second-generationTina-quant and
Cobash232 (Roche), STA-LiatestD-Dimer (Stago),D-DimerHS
500 (IL Diagnostics) and Innovance D-Dimer (Siemens). Pa-
tientswith anegativeD-dimer test result did not undergo any
further testing and were left without anticoagulant therapy.
Patients with a positive D-dimer result underwent CTPA. Pa-
tients with a positive CTPA result were started on anticoagu-
lant therapy, andpatientswithanegativeCTPAresultwere left
without anticoagulant treatment. Patients with inconclusive
CTPA(technically inadequate for interpretationor isolatedsub-
segmental PE) results underwent additional testingwith com-
pressionultrasonography, ventilation-perfusion lung scan, or
pulmonary angiography. Given the uncertainty regarding the
clinical relevance and optimal management of isolated sub-
segmental PE, it was decided to consider CTPA showing iso-
lated subsegmental PEas inconclusive and to recommend fur-
ther testing. The diagnostic strategy is depicted in theFigure.
Follow-up
All patients underwent follow-up for 3months. Patientswere
instructed to return to the clinic or to the emergency depart-
ment in case of recurrent symptoms of the respiratory sys-
tem or legs. At the end of follow-up, all patients included in
the study were interviewed by telephone by a study coordi-
nator using a structuredquestionnaire. Patientswere asked to
disclose all health-related events since their hospital dis-
charge: consultations with any physician, admission to hos-
pital, change in medication, diagnostic testing, or hemor-
rhagic complication. The family physician was contacted
whenever a possible thromboembolic eventwas disclosed by
the interim history, and charts were reviewed if a patient was
readmitted to the hospital for any cause.
All suspected venous thromboembolic events anddeaths
were adjudicatedby 3 independent expertswhowere blinded
to the criteria used to rule out PE at inclusion.
Outcomes
The primary outcome was the failure rate of the diagnostic
strategy,definedas therateofadjudicatedsymptomatic throm-
boembolic eventsduring the3-month follow-upperiodamong
patientsnot treatedwithanticoagulantson thebasis of anega-
tive D-dimer test result according to the age-adjusted cutoff.
Itwas computed as the number of adjudicated proximal deep
vein thrombosis (DVT) or PE (involving a segmental or more
proximal pulmonary artery), divided by the number of pa-
tientswithanegativeD-dimer result thatwere leftwithout an-
ticoagulant therapy.
Secondary outcomes included the proportion of patients
with a low-intermediate or unlikely probability and a D-
dimer result between 500 μg/L and their age-adjusted cutoff
value. This proportion represents the additional diagnostic
yield of the age-adjusted cutoff. We specifically assessed the
3-month thromboembolic risk in this subgroup of patients.
Wealsodefinedelderlypatientsaspatients75yearsorolder
and we analyzed the additional diagnostic yield of the age-
adjusted D-dimer cutoff in these patients.
Diagnoses of venous thromboembolic events during fol-
low-up were established with the usual criteria: for DVT, on
the basis of abnormal results on proximal compression ultra-
sonography; and for PE, on the basis of ventilation-perfusion
lung scan showing a high-probability pattern or CTPA or an-
giography showing segmental ormore proximal intraluminal
defects. Deaths were adjudicated as surely related, probably
related, possibly related, or unrelated toPE.Deathwas judged
to be related to PE if it was confirmed by autopsy, or if death
followed a clinically severe PE, either initially or after an ob-
jectivelyconfirmedrecurrentevent.Death inapatientwhodied
suddenlyorunexpectedlywas classified aspossibly related to
PE.Unrelateddeathsweredue to anobvious cause other than
PE. Three independent experts blinded to D-dimer levels ad-
judicated the outcome events.
Statistical Analysis
General characteristics were assessed using mean and stan-
darddeviation ormedian and interquartile range for continu-
ousvariablesandproportions forcategoricalvariables.Weused
theWilsonscoremethodwithoutcontinuitycorrection tocom-
pute the 95%CI around estimated proportions.13 Sample size
was estimated on the basis of our previous retrospective vali-
dationdata set.Weaimedat including enoughpatients topro-
vide accurate estimates of our primary and secondary out-
comes. To validate the safety of ruling out PE on the basis of a
D-dimer level between 500 μg/L and the age-adjusted cutoff,
the upper limit of the 95% CI around the 3-month thrombo-
embolic risk (failure rate) in patients left untreated on the ba-
sis of suchaD-dimer result shouldnot behigher than3%.This
failure rate corresponds to that observed after a negative pul-
monary angiography14 and is a widely accepted criterion for
thevalidationofdiagnostic strategies forPE.1,2,15-17 Thiswould
be obtained if nomore than 2 out of 240 patients with such a
D-dimer result would experience venous thromboembolism
during follow-up. In our previous retrospective study, 10% of
patientsolder than50yearswithanunlikelyor anonhighclini-
calprobabilityhadaD-dimer resultbetween500μg/Landtheir
age-adjusted cutoff. Hence, to include 240 patients with a D-
dimerbetween500μg/Land theage-adjustedcutoff, 2400pa-
tients older than 50years andwith anonhighorunlikely clini-
cal probability needed to be included. Because these patients
represented two-thirdsof all patientswith suspectedPE inour
previous study, a total of 3200 patients with suspected PE
needed to be included.
Results
Between January 1, 2010, and February 28, 2013, we screened
4420 patients. Among the 4420 screened patients, 1074were
excluded from the study for various reasons, described in the
Figure. Hence, 3346 patients were included in the study.
Twenty-two patients were excluded from further analy-
sis: the D-dimer test was not performed in 21 patients, and 1
patient withdrew his consent during the study period. Gen-
eral characteristics of the remaining 3324 patients are de-
picted in Table 2.
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DiagnosticWork-up at Initial Presentation
The study flowchart is summarized in the Figure. The clinical
probabilitywasnonhigh (ie, lowor intermediate)using thesim-
plified, revisedGenevascoreorunlikelyusing the2-levelWells
score for PE in 2898 (87.2%) patients. Among these 2898 pa-
tients with a nonhigh or unlikely clinical probability, 1154
(39.8%)patientshadanegativeD-dimer result according to the
age-adjusted cutoff (95% CI, 38.1%-41.6%): 817 (28.2%) pa-
tientshadaD-dimer level lower than500μg/L (95%CI, 26.6%-
29.9%) and 337 patients (11.6%) had a D-dimer between
500 μg/L and their age-adjusted cutoff (95% CI, 10.5%-
12.9%). Therefore, the use of the age-adjusted cutoff resulted
in an 11.6%absolute increase (95%CI, 10.5%-12.9%) or a41.2%
relative increase (95% CI, 31.3%-52.0%) in the proportion of
negative D-dimer results. The breakdown for the 6 D-dimer
tests used is depicted in Table 3.
Further testing was performed in the remaining 1744 pa-
tients with a D-dimer level higher than the age-adjusted cut-
Figure. Flow of Patients Through the Study
631 Pulmonary embolism1539 No pulmonary embolism
3324 Had clinical probability assessment
4420 Patients assessed for eligibility
622 Positive result1450 Negative result 14 Inconclusive
84 Not done
1074 Excluded
22 Excluded from further analysis
7 Aged <18 years
122 Ongoing anticoagulant therapy
8 Life expectancy <3 months
15 Pregnant
134 Diagnostic testing performed before inclusion
113 Discharged from emergency department
before inclusion
137 Contraindication to CTPA
25 Unavailable for follow-up
301 Unable to give informed consent
147 Refused to participate
65 Other reasons
1 Withdrew consent
21 Protocol violation (D-dimer not performed)
49 Allergy to contrast
88 Renal failure
89 Placed in no pulmonary
embolism group by
other tests
9 Placed in pulmonary
embolism group by
other tests
1744 ≥Age-adjusted cutoff817 D-dimer <500 μg/L 337 D-dimer ≥500 μg/L but
<age-adjusted  cutoff
2170 Underwent CTPA
426 Pulmonary embolism likely
or high clinical probability
2898 Pulmonary embolism unlikely




























58 Excluded from analysis
2 Lost to follow-up
56 Received anticoagulation
during follow-up
7 Excluded from analysis
4 Lost to follow-up
3 Received anticoagulation
6 Excluded from analysis
0 Lost to follow-up
6 Received anticoagulation
Abbreviation: CTPA, computed tomographic pulmonary angiography.
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off and in the 426 patientswith a likely or a high clinical prob-
ability of PE. Computed tomographypulmonary angiography
results were positive in 622 patients and negative in 1450 pa-
tients.Computed tomographypulmonaryangiographywas in-
conclusive (n = 14) or not performed (n = 84, protocol viola-
tions) in 98patients.Nineof the98patients hadPEconfirmed
on the basis of a high-probability ventilation-perfusion lung
scan (n = 2) or a proximal DVT on compression ultrasound
(n = 7). Pulmonary embolism was ruled out in the remaining
89patients on the basis of a negative result fromapulmonary
angiogram (n = 1), ventilation-perfusion lung scan (n = 12),
compressionultrasound (n = 26), D-dimer test result (despite
likely/high clinical probability; n = 8), or without any further
additional testing (n = 42). Therefore, PEwasdiagnosed in631
patients, and the overall prevalence of PE in our study was
19.0% (95% CI, 17.7%-20.4%).
Three-Month Follow-up
D-Dimer Level Lower Than 500 μg/L
During the 3-month follow-upperiod, of the 817 patientswith
a D-dimer level lower than 500 μg/L, 3 patients received an-
ticoagulants for another reason than PE, and 4 (0.5%) pa-
tients were lost to follow-up. Among the 810 remaining
patients, there were 2 deaths and 8 suspected VTE during
follow-up. Of these 10 events, 1 was adjudicated as having a
confirmed nonfatal PE. Therefore, the 3-month thromboem-
bolic risk was of 1 of 810 patients (0.1% [95% CI, 0.0%-0.7%]).
D-Dimer Level Between 500 μg/L and the Age-Adjusted Cutoff
Of the 337patientswith aD-dimer level between500μg/L and
their age-adjusted cutoff, nopatientwas lost to follow-upand
6patients receivedanticoagulation for another indication than
PE.Of the remaining331patients, 7diedand7underwent test-
ing for suspected venous thromboembolism. One of these 14
events was adjudicated as a confirmed nonfatal PE. Adjudi-
cated causes of death were as follows: 3 were due to end-
stage chronic obstructive pulmonary disease, 1 was from re-
fractory idiopathic thrombopenic purpura with severe
thrombocytopenia complicated by intestinal hemorrhage, 1
was due to a metastatic melanoma, 1 was due to terminal ca-
chexia in the context of a psychiatric illness, and 1 was due to
a hypovolemic shock after a massive hemorrhage associated
with over-anticoagulation for atrial fibrillation (anticoagula-
tion was initiated during follow-up).
Therefore, the failure rate of the age-adjusted cutoff was
1 of 331 patients (0.3% [95% CI, 0.1%-1.7%).
PatientsWith a D-Dimer Level Above the Age-Adjusted Cutoff
and PatientsWith a Likely or High Clinical Probability
Of the 1539 patients with a D-dimer level above the age-
adjusted cutoff or with a high or likely clinical probability in
whom the diagnosis of PE was ruled out, 2 patients were lost
to follow-upand56patientswere given anticoagulants for an-
other reason than PE. Of the remaining 1481 patients, 18 died
and40presentedwitha suspicionof a thromboembolic event.
Seven of these 58 suspected events were adjudicated as con-
firmed or possible events: PE (n = 4), DVT (n = 1), indetermi-




Overall, 766 patients were 75 years or older. Of these
patients, 673 patients (87.9%) had a nonhigh clinical prob-
ability. The proportion of patients with D-dimer level lower





Age, median (IQR), y 63 (53-74)
Personal history of VTE 466 (14.0)
Active malignancy 429 (12.9)
Surgery within 1 month 392 (11.8)
Estrogen use 183 (5.5)




Heart rate, mean (SD), beats/min 87.1 (19.6)
Respiratory rate, mean (SD), beats/min 19.2 (6.2)
Abbreviations: IQR, interquartile range; VTE, venous thromboembolism.













Total Patients % (95% CI)
No. of Events/
Total Patients % (95% CI)
VIDAS D-Dimer
Exclusion
1345 423 0/417 0.0 (0.0-0.9) 130 0/127 0.0 (0.0-2.9)
Innovance D-Dimer 838 202 1/202 0.5 (0.1-2.8) 103 1/103 1.0 (0.2-5.3)
STA-Liatest
D-Dimer
389 132 0/132 0.0 (0.0-2.8) 49 0/47 0.0 (0.0-7.6)
D-Dimer HS 500 185 32 0/31 0.0 (0.0-11.0) 23 0/23 0.0 (0.0-14.3)
Second-generation
Tina-quant
128 26 0/26 0.0 (0.0-12.9) 32 0/31 0.0 (0.0-11.0)
Cobas h 232 13 2 0/2 0.0 (0.0-65.8) 0
Total 2898 817 1/8 0 0.1 (0.0-0.7) 337 1/331 0.3 (0.1-1.7)
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than 500 μg/L was 43 of 673 patients (6.4% [95% CI, 4.8%-
8.5%]). Another 157 patients (23.3%) had a D-dimer level
lower than their age-adjusted cutoff. Therefore, the propor-
tion of patients older than 75 years with a nonhigh or
unlikely clinical probability and a negative D-dimer result
using the age-adjusted cutoff was 200 of 673 patients (29.7%
[95% CI, 26.4%-33.3%]). Of these patients, 5 received antico-
agulant therapy for another indication than venous throm-
boembolism. None of the remaining 195 patients had a con-
firmed venous thromboembolism during follow-up: 0 of 195
patients (0.0% [95% CI, 0.0%-1.9%]).
Discussion
In this prospective study, using an age-adjusted D-dimer cut-
off in emergency department patients with suspected PE in-
creased thediagnosticyieldofD-dimer testing.AD-dimer level
higher than 500 μg/L but below the age-adjusted cutoff ruled
out the diagnosis of PE,with a 3-month risk of venous throm-
boembolism in line with that observed in patients with a D-
dimer level lower than 500 μg/L or after a negative pulmo-
nary angiography result, the gold-standard test for PE. In
patients 75 years or older, the age-adjusted cutoff increased
5-fold the proportion of patients in whom PE could be ruled
out without further imaging.
These results are in line with those obtained in the ini-
tial derivation and retrospective external validation study.9
After the publication of this initial report, other retrospec-
tive validation analyses were published, including more
than 10 000 patients with suspected venous thromboembo-
lism, using various D-dimer assays in various clinical set-
tings (suspected DVT, suspected PE) in many different coun-
tries, which all indicated a potential clinical usefulness of
the age-adjusted cutoff, particularly for elderly patients.18,19
However, a prospective management outcome study, in
which patients with suspected PE would be managed with-
out anticoagulants on the basis of a negative D-dimer test
result using the age-adjusted cutoff, was missing. In our
study, the diagnostic conclusion and therapeutic manage-
ment was decided on the basis of the age-adjusted cutoff.
Another proposed approach in the literature was to use
fixed increased cutoff values in elderly patients (eg, 750
μg/L in patients 60 years or older).20 However, this cutoff
value was never prospectively validated. Moreover, the
strength of the age-adjusted cutoff is that it was derived
using receiver operating characteristics (ROC) curve analysis
in each age group and linear regression analysis. Another
strength is that the age-adjusted cutoff is easy to memorize
(patient’s age multiplied by 10) and is tailored to each indi-
vidual patient.
Elderly patients may have the greatest potential benefit
of the use of the age-adjusted cutoff. In patients 75 years or
older, the proportion of patients with a D-dimer level lower
than 500 μg/L was 43 of 673 patients (6.4%). The proportion
of patients with negative D-dimer result was 29.7% when
using the age-adjusted cutoff. In other words, although only
1 in 16 patients could have the diagnosis of PE ruled out on
the basis of the D-dimer as a sole test when using the con-
ventional cutoff, this proportion increased to 1 in 3.4
patients when using the age-adjusted cutoff. Previous stud-
ies have shown that in all patients, irrespective of age, the
number needed to test with a D-dimer test to rule out 1 PE is
approximately 3,4 but in elderly patients, this number could
be as high as 20 after 80 years.8 Thus, the use of the age-
adjusted cutoff allows to “restore” the yield of the D-dimer
test in elderly patients. This is particularly important in clini-
cal practice. Indeed, elderly patients are more likely to pre-
sent with renal impairment and to develop contrast-induced
nephropathy,21 limiting the use of CTPA in this age group.
The use of the ventilation-perfusion lung scan is limited by
the higher number of inconclusive results obtained in this
age group.22 The possibility of ruling out PE on the basis of a
simple blood test could allow shortening a patient’s stay in
the ermergency department and limiting the unnecessary
exposure to radiation, contrast agents of the CTPA, and anti-
coagulant therapy. On the other hand, it was important to
ensure that the increased yield of the D-dimer test would
not compromise patient safety, given the risks of untreated
PE in this patient population.
This study has several strengths. This was a large inter-
national collaboration. All consecutive patients seen at par-
ticipating centers were approached for inclusion, and all
suspected thromboembolic events and deaths during
follow-up were adjudicated by an independent committee.
Our sample size was calculated to enable assessment of the
age-adjusted cutoff failure rate in the subgroup of patients
with a D-dimer level higher than 500 μg/L but below the
age-adjusted cutoff.
This study also has several limitations. First, 2 different
pretest probability assessment tools and 6 different com-
mercial D-dimer assays were used. Therefore, not all
included patients were managed using the exact same diag-
nostic tests. However, the 2 probability assessment tools
and the high-sensitive D-dimer tests used have been dem-
onstrated to be equivalent.23,24 As shown in Table 3, results
were homogeneous across the different D-dimer assays.
Therefore, this could increase the generalizability of our
finding to a wide number of settings with different prac-
tices. Second, this study was not designed as a randomized
clinical study. Therefore, we could not compare the
3-month thromboembolic risk with that of a control group
that would have been managed using the conventional
500 μg/L cutoff. However, the low rate of venous thrombo-
embolic events renders a significant difference between the
2 strategies unlikely. Moreover, the use of the 3-month
thromboembolic risk is widely used as the standard refer-
ence for the validation of PE diagnostic strategies.1,2 Third,
although all suspected events during follow-up were adjudi-
cated by an independent committee, only 1 of the 7
deceased patients with D-dimer levels higher than 500 μg/L
and below the age adjusted D-dimer cutoff had an autopsy
(1 of the 3 patients with end-stage chronic obstructive pul-
monary disease). Therefore, it is impossible to formally
exclude PE as the cause of death in the 6 remaining
patients. However, all the 7 deaths were adjudicated as
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unrelated to PE (obvious cause other than PE). Fourth, in
patients with suspected recurrences during follow-up, con-
sidering CTPA showing isolated subsegmental pulmonary
embolism as inconclusive might be regarded as a potential
limitation. However, this scenario did not occur during
follow-up of patients with D-dimer levels lower than 500
μg/L or below the age-adjusted cutoff. Therefore, our infer-
ences regarding the failure rate in patients having D-dimer
levels between the usual cutoff and the age-adjusted cutoff
are likely to be robust. Fifth, the prevalence of PE was some-
what higher than that usually observed in North American
studies.25-27 However, it is in line with previous studies in
Europe.1,2 Moreover, a lower prevalence would have likely
resulted in an even lower failure rate of the age-adjusted
D-dimer cutoff.
Conclusions
In this study, an age-adjusted D-dimer cutoff combined with
probability assessment ruled out the diagnosis of PE in emer-
gency department patients with suspected PE and was asso-
ciatedwith a low likelihoodof subsequent symptomatic VTE,
andwith an increased proportion of patients inwhom the di-
agnosis could be excluded. This was particularly true in el-
derlypatients,witha5-fold increase in theproportionofnega-
tive D-dimer test results in patients 75 years or older. Future
studies should assess the clinical usefulness of the age-
adjustedD-dimer cutoff in clinical practice.Whether the age-
adjusted cutoff can result in improved cost-effectiveness or
quality of care remains to be demonstrated.
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